Beleaguered brewers want Germany's 500-year-old beer purity law, the Reinheitsgebot, included on UNESCO's World Heritage List
With JC Penney's same-store sales up and e-commerce growing, investors worry that the company is sacrificing unit profit for volume
The president calls income inequality "the defining challenge of our time" and links it to decreased social mobility
The simple idea that changed the way people communicate: What if you could get your work e-mail while not at work?
Walter Friedman's Fortune Tellers chronicles the careers of America's first economic forecasters
Amazon is eager to dispatch drones bearing small retail orders, but it's not even clear if any penalties might apply to property owners who shoot down pilotless aircraft flying over their land
It's releasing its new Turbo Fast series in batches around the holidays, when kids do their most viewing
Northwestern's Kellogg School of Management reclaims the top stop after a two-year absence
Author Laurel Delaney discusses the opportunities and risks for small businesses in a "born global" market of 2.4 billion online consumers
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."